BCMU
VIRX

BlueCrest Capital Management (UK)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-136
Closed -$141K – 480
2013
Q3 		$141K Buy
+136
New +$145K 0.01% 330

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlueCrest Capital Management (UK)'s VIRX Position: Q4 2013 in Review

BlueCrest Capital Management (UK) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2013, closing a stake of 136 shares — an estimated $141K sold.

BlueCrest Capital Management (UK) first reported a position in VIRX in Q3 2013 and held it in 1 quarter. The position peaked at $141K in Q3 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q4 2013.

  • BlueCrest Capital Management (UK) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 136 Viracta Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $141K.
  • BlueCrest Capital Management (UK) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Viracta Therapeutics, Inc. Common Stock position peaked at $141K in Q3 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2013.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q4 2013, filed 14 Feb 2014.